Chargement en cours...
Metastatic Breast Cancer Coexisting With HER-2 Amplification and EGFR Exon 19 Deletion Benefits From EGFR-TKI Therapy: A Case Report
Background: Patients with different molecular subtypes of breast cancers have different recurrence risks and prognoses. Clinical support and evidence to guide management are absent for patients with breast cancer coexisting with HER-2 amplification and EGFR mutations. Case presentation: We report a...
Enregistré dans:
| Publié dans: | Front Oncol |
|---|---|
| Auteurs principaux: | , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Frontiers Media S.A.
2020
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7274020/ https://ncbi.nlm.nih.gov/pubmed/32547945 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2020.00771 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|